Radioligand therapy slows advanced PSMA+ prostate cancer

Radioligand therapy slows advanced PSMA+ prostate cancer

(HealthDay)—Lutetium-177 (177Lu)-prostate-specific membrane antigen (PSMA)-617 radioligand therapy added to standard care is beneficial for patients with advanced PSMA-positive metastatic castration-resistant prostate cancer, according to a study published online June 23 in the New England Journal of Medicine.

Oliver Sartor, M.D., from Tulane University in New Orleans, and colleagues conducted an international, phase 3 trial involving with metastatic castration-resistant prostate cancer previously treated with at least one androgen receptor-pathway inhibitor and one or two taxane regimens. A total of 831 patients were randomly assigned to receive 177Lu-PSMA-617 plus protocol-permitted standard care, which excluded chemotherapy, immunotherapy, radium-223, and investigational drugs, or standard care alone. Patients were followed for a median of 20.9 months.

The researchers found that compared with standard care, 177Lu-PSMA-617 plus standard care significantly prolonged imaging-based (median, 8.7 versus 3.4 months; hazard ratio for progression or death, 0.40) and overall survival (median, 15.3 versus 11.3 months; hazard ratio for death, 0.62). 177Lu-PSMA-617 was significantly favored for all key secondary end points. A higher incidence of adverse events of grade 3 or above was seen with versus without 177Lu-PSMA-617 (52.7 versus 38.0 percent), while quality of life was not adversely affected.

"The trial aimed to assess the efficacy of 177Lu-PSMA-617 plus therapies that could safely be combined in order to provide physicians with a broad permitted range of concomitant treatment options," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including Endocyte, which funded the study.

Explore further

Targeted 'radioligand' improves survival in advanced prostate cancer

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: New England Journal of Medicine

Copyright © 2021 HealthDay. All rights reserved.

Citation: Radioligand therapy slows advanced PSMA+ prostate cancer (2021, July 6) retrieved 4 October 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors